Veracyte(VCYT)
SOUTH SAN FRANCISCO, CADiagnostics
Focus: Veracyte is a public diagnostics company specializing in molecular and genomic testing platforms for cancer risk stratification and patient management. The company operates at ~750 employees with $361M in FY2025 revenue, positioning it as a mid-cap diagnostics player.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
46+24 this month
Hot — 56 jobs added in 30d
Net +24 (56 new, 32 removed). Aggressive expansion phase.
Should You Work at Veracyte?
AI assessmentVeracyte suits professionals seeking stability in diagnostics with established revenue, but limited upside for those pursuing drug development innovation.
Why Work Here
- Established revenue base ($361M in FY2025, +22% YoY) provides operational stability uncommon in early-stage biotech
- Diversified diagnostic portfolio across prostate, breast, and pulmonary indications reduces single-product dependency risk
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$361M
Key Products
Decipher
Growing
Growth
Flagship genomic classifier driving prostate cancer risk stratification; appears in multiple clinical utility programs.
Percepta Nasal Swab
Help build intelligence for Veracyte
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.